Lexaria Bioscience Corp. (LEXX)
NASDAQ: LEXX · Real-Time Price · USD
1.350
-0.340 (-20.12%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Lexaria Bioscience Revenue
Lexaria Bioscience had revenue of $174.00K in the quarter ending February 28, 2025, with 20.00% growth. This brings the company's revenue in the last twelve months to $525.92K, up 29.95% year-over-year. In the fiscal year ending August 31, 2024, Lexaria Bioscience had annual revenue of $464.28K with 105.24% growth.
Revenue (ttm)
$525.92K
Revenue Growth
+29.95%
P/S Ratio
40.90
Revenue / Employee
$75,132
Employees
7
Market Cap
23.70M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Aug 31, 2024 | 464.28K | 238.07K | 105.24% |
| Aug 31, 2023 | 226.21K | -29.19K | -11.43% |
| Aug 31, 2022 | 255.40K | -467.34K | -64.66% |
| Aug 31, 2021 | 722.74K | 407.95K | 129.59% |
| Aug 31, 2020 | 314.79K | 92.18K | 41.41% |
| Aug 31, 2019 | Pro | Pro | Pro |
| Aug 31, 2018 | Pro | Pro | Pro |
| Aug 31, 2017 | Pro | Pro | Pro |
| Aug 31, 2016 | Pro | Pro | Pro |
| Aug 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.90B |
LEXX News
- 23 hours ago - Lexaria Announces $2 Million Registered Direct Offering of Common Stock - Accesswire
- 2 days ago - Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience's Technology - Accesswire
- 22 days ago - Lexaria Updates its Ongoing Human Study GLP-1-H24-4 - Accesswire
- 23 days ago - Lexaria's Human GLP-1 Study #5 Begins Dosing - Accesswire
- 5 weeks ago - Lexarias' DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound - TheNewswire
- 5 weeks ago - Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound(R) - Accesswire
- 2 months ago - The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience - Accesswire
- 2 months ago - Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm - Accesswire